KIORA PHARMACEUTICALS INC Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2016 to Q3 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Kiora Pharmaceuticals Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2016 to Q3 2025.
- Kiora Pharmaceuticals Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2025 was -$616K, a 81.9% increase year-over-year.
- Kiora Pharmaceuticals Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2025 was -$7.11M.
- Kiora Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $5.66M.
- Kiora Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$12.4M, a 9.3% increase from 2022.
- Kiora Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$13.7M, a 1.91% increase from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)